Pharmacological therapy and cardiovascular risk reduction for type 2 diabetes
Eduardo Bello Martins, Eduardo Gomes Lima, Fábio Grunspun Pitta, Letícia Neves Solon Carvalho, Thiago Dias de Queiroz, Carlos Serrano
Abstract
The pharmacological therapy for type 2 diabetes mellitus has presented important advances in recent years, which has impacted the treatment of patients with established cardiovascular disease or with high cardiovascular risk. In this scenario, two drug classes have emerged and demonstrated clear clinical benefits: SGLT-2 inhibitors and GLP-1 agonists. The present review discusses the pharmacology, adverse effects, and clinical trials that have demonstrated the benefits of these medications in reducing cardiovascular risk.
Topics & Concepts
MedicineType 2 diabetesDiseaseDiabetes mellitusIntensive care medicineAdverse effectClinical trialType 2 Diabetes MellitusDrugPharmacotherapyPharmacologyInternal medicineEndocrinologyDiabetes Treatment and ManagementDiabetes Management and ResearchDiet and metabolism studies